MedDataX Logo

Reduction of Bedrest Time of Post Percutaneous Renal Biopsy Patients

NCT ID: NCT04629235

Last Updated: 2020-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2022-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the reduction of the bedrest time of the patient after percutaneous renal biopsy from 24 hours to 8 hours in relation to the occurrence of complications evaluated by the Nursing Outcome Classification (NOC) indicators.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Percutaneous renal biopsy (BRP) is an important procedure for the diagnosis, prognostic evaluation and therapeutic orientation of several kidney diseases. Although it is considered a safe procedure, BRP complications can occur and, most of the time, are related to the risk of bleeding and the main consequence of BRP. Complications include macroscopic hematuria and hematoma requiring blood transfusion, surgical intervention, or invasive procedure. Since hemorrhagic complications continue to be the highest risk after BRP due to severity and potential life-threatening risk, there is an effort to minimize the risk of bleeding by checking blood clotting markers prior to the procedure, uncontrolled hypertension and the use of antiplatelet drugs and anticoagulants. The relevance of this study is to seek better evidence for clinical practice, considering the lack of Brazilian studies on the subject and the positive impact on patient comfort, besides the reduction of costs for the institution and overload in the work of the multidisciplinary team. In addition, it will contribute to the strengthening of the use of NOC in clinical practice and to the improvement of nursing knowledge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bedrest

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Renal Biopsy Complications Standardized Nursing Terminology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

24 hours of bedrest

\- 24 hours of bedrest

Group Type ACTIVE_COMPARATOR

bedrest

Intervention Type BEHAVIORAL

24 hours of bedrest

Intervention group

\- Wonder around after 8 hours of bedrest

Group Type EXPERIMENTAL

wonder around

Intervention Type OTHER

wonder around after 8 hours of bedrest

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

wonder around

wonder around after 8 hours of bedrest

Intervention Type OTHER

bedrest

24 hours of bedrest

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients undergoing renal biopsy at Hospital de Clínicas de Porto Alegre (HCPA);
* Both sexes;
* Aged 18 years or older.

Exclusion Criteria

* Patients with the following risk factors for complications;
* More than two punctures during the procedure;
* Larger gauge needle;
* Uncontrolled blood pressure;
* Blood clotting disorders and use of antiplatelet agents (aspirin or clopidogrel), or use of anticoagulants;
* Bedridden patients and patients unable to adequately to ambulate.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital de Clinicas de Porto Alegre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amália de Fátima Lucena

Role: PRINCIPAL_INVESTIGATOR

Hospital de Clínicas de Porto Alegre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Magáli Costa Oliveira

Role: CONTACT

Phone: +5551982378146

Email: [email protected]

Amália de Fátima Lucena

Role: CONTACT

Phone: +5551981794710

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

170430

Identifier Type: -

Identifier Source: org_study_id